panitumumab
amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve ']
improve ph2 trial: intermit vs cont pmab plus folfiri 1l ras/brafwt mcrc pfs 17.6 vs 12.6 mo favoring intermit. group less g3-4 tox with intermit(skin 13/27%) consider time off chemo or de-escalate (marathon! not a sprint) ctdna will help to guide #asco22
Brazilian Medical Oncologist, Advanced Fellow at GI Medical Oncology Service - MSKCC #gicancers